Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Wednesday, Aug 30, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

Since 2013, pertuzumab (Perjeta)-based chemotherapy has dominated the treatment landscape in the preoperative setting, based on the results of the NeoSphere and TRYPHAENA trials, states Tolaney.

However, now there are data from the APHINITY trial looking at the long-term benefits of pertuzumab in the adjuvant setting. Since the results of this trial demonstrate that not all patients will experience a long-term benefit with pertuzumab, this could potentially change the approach to treatment in the neoadjuvant setting.
 


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy for patients with breast cancer.

Since 2013, pertuzumab (Perjeta)-based chemotherapy has dominated the treatment landscape in the preoperative setting, based on the results of the NeoSphere and TRYPHAENA trials, states Tolaney.

However, now there are data from the APHINITY trial looking at the long-term benefits of pertuzumab in the adjuvant setting. Since the results of this trial demonstrate that not all patients will experience a long-term benefit with pertuzumab, this could potentially change the approach to treatment in the neoadjuvant setting.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x